ArticleEmerging infectious diseases2015
Risk factors for death from invasive pneumococcal disease, Europe, 2010.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pneumococcal serotypes and their association with death risk in invasive pneumococcal disease: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Global Case Fatality of Bacterial Meningitis During an 80-Year Period: A Systematic Review and Meta-Analysis.JAMA network open · 2024Pooled it
- Antimicrobial resistance in paediatricThe Lancet. Microbe · 2021Pooled it
- Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world.Human vaccines & immunotherapeutics · 2017Pooled it
- Trial
- Modelling impacts of paediatric amoxicillin shortage management on pneumococcal resistance and invasive disease in Europe.Nature communications · 2026Article
- Genomic characterization of invasive disease-causingMicrobial genomics · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026Review
- Emergence of a piliated and multidrug-resistantMicrobiology spectrum · 2025Article
- Clinical characteristics and risk factors for poor outcomes of invasive pneumococcal disease in pediatric patients in China.BMC infectious diseases · 2024Article
- Antimicrobial Resistance ofInfection & chemotherapy · 2024Article
- Disease-Associated Streptococcus pneumoniae Genetic Variation.Emerging infectious diseases · 2024Article
- Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study.BMJ open · 2023Article
- Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review.Microorganisms · 2023Review
- Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan.Antimicrobial agents and chemotherapy · 2023Article
- Invasive pneumococcal disease and long-term outcomes in children: A 20-year population cohort study.Lancet regional health. Americas · 2022Article
- Clinical characteristics, antimicrobial resistance, and risk factors for mortality in paediatric invasive pneumococcal disease in Beijing, 2012-2017.BMC infectious diseases · 2022Article
- Age-Dependent Serotype-Associated Case-Fatality Rate in Invasive Pneumococcal Disease in the Autonomous Community of Madrid between 2007 and 2020.Microorganisms · 2021Article
- Invasive pneumococcal disease: a diagnostic challenge due to multiple portals of causative bacteria.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the possible association between patient age and sex, clinical presentation, Streptococcus pneumoniae serotype, antimicrobial resistance, and death in invasive pneumococcal disease cases reported by 17 European countries during 2010. The study sample comprised 2,921 patients, of whom 56.8% were men and 38.2% were >65 years of age. Meningitis occurred in 18.5% of cases. Death was reported in 264 (9.0%) cases. Older age, meningitis, and nonsusceptibility to penicillin were significantly associated with death. Non-pneumococcal conjugate vaccine (PCV) serotypes among children <5 years of age and 7-valent PCV serotypes among persons 5-64 years of age were associated with increased risk for death; among adults >65 years of age, risk did not differ by serotype. These findings highlight differences in case-fatality rates between serotypes and age; thus, continued epidemiologic surveillance across all ages is crucial to monitor the long-term effects of PCVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.